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uPAThe epithelial-to-mesenchymal transition (EMT), a process involving the breakdown of cell–cell junctions and
loss of epithelial polarity, is closely related to cancer development and metastatic progression. While the cystic
ﬁbrosis transmembrane conductance regulator (CFTR), a Cl− and HCO3− conducting anion channel expressed
in a wide variety of epithelial cells, has been implicated in the regulation of epithelial polarity, the exact role of
CFTR in the pathogenesis of cancer and its possible involvement in EMT process have not been elucidated.
Here we report that interfering with CFTR function either by its speciﬁc inhibitor or lentiviral miRNA-mediated
knockdown mimics TGF-β1-induced EMT and enhances cell migration and invasion in MCF-7. Ectopic
overexpression of CFTR in a highly metastatic MDA-231 breast cancer cell line downregulates EMT markers
and suppresses cell invasion and migration in vitro, as well as metastasis in vivo. The EMT-suppressing effect of
CFTR is found to be associated with its ability to inhibit NFκB targeting urokinase-type plasminogen activator
(uPA), known to be involved in the regulation of EMT. More importantly, CFTR expression is found signiﬁcantly
downregulated in primary human breast cancer samples, and is closely associated with poor prognosis in differ-
ent cohorts of breast cancer patients. Taken together, the present study has demonstrated a previously undeﬁned
role of CFTR as an EMT suppressor and its potential as a prognostic indicator in breast cancer.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
The epithelial-to-mesenchymal transition (EMT) is one of the most
critical processes that occur during the progression of tumor metastasis
[1,2]. In breast carcinomas, acquisition of a mesenchymal-like pheno-
type that is reminiscent of an EMT, designated as oncogenic EMT, is as-
sociated with pro-metastatic properties, including increased motility,
invasion, and cancer stem cell characteristics [3,4]. EMT has been char-
acterized as a complicated multistep process rather than simply a mor-
phological transition. Besides the cytoskeleton rearrangement and the
subsequent morphological changes, EMT is often originated from the
disruption of epithelial adhesion and other polarized structures, such
as tight junctions and adherens junctions, followed by the acquisition
of migratory and invasive properties of the cells [5]. While the full spec-
trum of signaling agents that contribute to the EMT of carcinoma cellschan@cuhk.edu.hk (H.C. Chan).
ights reserved.remains unclear, numerous lines of evidence have revealed an essential
role of NFκB during distinct steps of EMT and cancer progression [6].
One of the major transcriptional targets of NFκB activation is uPA. It has
been well established that the uPA/uPAR axis plays a central role in the
EMT process during cancer development [7]. Moreover, overexpression
of uPA and uPAR has been shown to be associatedwith adverse prognosis
in various malignancies, including breast cancer [8–10]. Interestingly,
apart from NFκB, it has been shown recently that uPA can be directly
targeted by a tumor suppressive miRNA, miR-193b [11,12].
Cystic ﬁbrosis transmembrane conductance regulator (CFTR) is a
cAMP-activated anion channel expressed in the epithelial cells of a
wide variety of tissues, mutations of which cause cystic ﬁbrosis (CF), a
common life-threatening autosomal recessive disease in Caucasianpop-
ulations [13]. Of note, there is an increasing interest in the association of
cancer incidence with the genetic variations in the CFTR gene. Large co-
hort studies in North American and European patients with CF found
that there was a marked increase in the risk of malignancies affecting
the gastrointestinal tract [14–16]. Particularly, in a recent study involv-
ing 41,188 cases of CF patients followed from 1990 to 2009 in the US,
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with most cases arising in the bowel [16]. However, CFTR gene muta-
tions have also been reported to be associated with a lower risk of sev-
eral cancers, such as melanoma [17], prostate cancer [18] and lung
cancer [19]. On the other hand, CFTR has been suggested to interact
with various cancer-related kinases [20,21]. Despite all these observa-
tions, the biological role of CFTR in cancer development is still unclear.
Interestingly, various studies have reported that defect/suppression
of CFTR in the epithelial cells results in aberrant activation of NFκB
[22–24]. Given that the uPA/uPAR axis plays a central role in EMT, and
uPA is known to be activated by NFκB during cancer development [7],
we reasoned that CFTR might also be involved in the regulation of
EMT and cancer metastasis through the NFκB/uPA pathway. Thus, we
undertook the present study to investigate the role and the underlying
mechanisms of CFTR in breast cancer EMT and metastasis. Our results
show that CFTR suppresses breast cancer metastasis both in vitro and
in vivo through modulation of EMT. Moreover, we demonstrate that
low expression of CFTR is associated with cancer progression and poor
survival of breast cancer patients.
2. Materials and methods
2.1. Cell lines and functional studies
We obtained human breast adenocarcinoma cell lines MCF-7 and
MDA-231 from the American Type Culture Collection (Manassas, VA,
USA) and cultivated them in DMEM/F12 supplemented with 10% fetal
bovine serum, 100 μg/ml streptomycin and 100 unit/ml penicillin.
EMT was induced using TGFβ1 (2 ng/ml). CFTR channel function was
blocked by CFTRinh-172 (10 μM) or GlyH101 (5–10 μM). For wound
healing assay, cells were seeded at 1 × 106 cells/well in 6-well plates
and then pre-incubated for 24 h before creating a wound across the
cell monolayer with a plastic tip. Cells were then grown in culture me-
dium with 1% FBS in the presence or absence of 10 μM inh172 or
10 μM GlyH101. The closure of the wound via the migration of cells
into the wound was tracked and recorded using a Time Lapse Imaging
System (CarlZwiss) at 1 hour intervals for 48 h. Cell migration was de-
termined bymeasuring distances between parallel lines from the initial
sites to the migrated sites. The experimental procedure was repeated
three independent times. We tested cell invasion in modiﬁed Boyden
chambers containing porous (8 μm), polycarbonate membranes
(Corning Incorporated) coated with 500 μg/ml matrigel (BD biosci-
ences, San Jose, USA). A total of 20,000 cells were added to the transwell
inserts over the top of the artiﬁcial basement membrane. The plate was
then incubated for 72 h forMCF-7 or 24 h forMDA-231 at 37 °C, 5% CO2
and 95% humidity. After 72 h or 24 h, the inserts were removed from
the plate and the inside of the insert was cleaned thoroughlywith tissue
paper. Any cells which had invaded through the membrane and passed
to the underside of the insert were ﬁxed in 4% paraformaldehyde (v/v)
in PBS for 5 min before being stained in 0.5% crystal violet solution
(w/v) in distilled water. At least ﬁve random ﬁelds per insert were
counted and triplicate inserts were set up for each test sample. The
experimental procedure was repeated for three times. Cell growth
rate was measured with an MTS proliferation assay. The Cell Titer 96
Aqueous One Solution Cell Proliferation Assay (Promega) was conducted
according to the manufacturer's instructions.
2.2. CFTR overexpression and knockdown
The pEGFPC3 plasmid expressingwild-type CFTRwas kindly provid-
ed by Professor Tzyh-Chang Hwang (University of Missouri-Columbia).
For overexpression experiments, the MDA-231 cells were transfected
with 3 μg DNA and 6 μl Lipofectamine 2000 (Invitrogen, Camarillo
CA), the transfected MDA-231 cells were selected in full medium
containing G418 (Calbiochem, Schwalbach, Germany) at 1200 μg/ml.
To knock down CFTR expression in MCF-7 cells, miRNA duplex speciﬁcto human CFTR was synthesized by Lift Technologies. The miRNA
sequence is as follows: 5′-TTG GAA AGG AGA CTA ACA AGT-3′. MiR
expression vector, named as pcDNA™6.2-GW/EmGFP, containing a
double-stranded oligonucleotide (ds oligo) encoding a pre-miRNA se-
quence was established using BLOCK-iT™ Pol II miR RNAi Expression
Vector kits (Life Technologies, Rockville, MD) following the standard
protocol. Lentiviral particles were produced by transient transfection
of 293FT (Invitrogen) cells using Lipofectemin 2000 (Invitrogen) re-
agent. Viral supernatants were collected 24 h post-transfection. One
day before transduction, MCF-7 cells were seeded into 35 mm culture
dishes at 60% to 80% conﬂuence. Viral supernatants were mixed with
fresh medium at the ratio of 1:1, and incubated with cells for 24 h.
Blasticidin at the ﬁnal concentration of 5 μg/ml was used to select the
stable clones.
2.3. Primary breast cancer samples
To determine the clinical relevance of CFTR in breast cancer, tissue
samples were collected from patients (n = 17) with primary breast
cancer from the Department of Pathology, Xijing Hospital, FourthMilitary
Medical University, Xi'an, Shaanxi, China. All sampleswere collectedwith
the informed consent of the patients and the study was approved by the
Ethics Committee. The clinical and histopathologic characteristics of
patients with breast cancer are presented in Appendix A: Supplementary
Table 2.
2.4. Immunohistochemistry and immunoﬂuorescent staining
Primary breast cancer sections (5 μM) were deparafﬁnized,
rehydrated and rinsed with PBS. Endogenous peroxidase activity was
quenched using 3% hydrogen peroxide and rinsed with PBS. Antigen re-
trieval was carried out in a retrieval citrate buffer (pH 6.0) at 95 °C for
15 min. The sections were rinsed with PBS and then incubated in 10%
normal goat serum blocking solution in a humidiﬁed box at room tem-
perature for 1 h. After blocking, anti-CFTR (Santa Cruz, 1:200) in PBS-T
solutionwas added and the sectionswere incubated in a humidiﬁed box
at 4 °C overnight. As negative staining controls, separate slides of tissue
sectionswere incubated in PBS containing 1% goat serum in the absence
of primary antibodies. The stainingwas visualized using DAB Plus Chro-
mogen, followed by counterstaining with hematoxylin. Slides were
evaluated for the staining intensity (0, none; 1, weak; 2, moderate;
and 3, strong) of positively stained cells. Two investigators indepen-
dently evaluated the tissue sections. For immunoﬂuorescent staining,
cells were ﬁxed in 4% paraformaldehyde and blocked with 1% bovine
serum albumin, and incubated overnight with primary antibodies at
4 °C. Then secondary Alexa ﬂuor 568 goat anti-mouse IgG, ﬂuor 488
goat anti-rabbit IgG or 568 donkey anti-rabbit IgG at a dilution of 1:500
was loaded on cells for 1 h. Samples were all co-stained with Hoechst
33342. Following three washings with PBS, the slides were mounted
and visualized with ﬂuorescence microscopy.
2.5. Animal studies
Nude mice were provided by the Laboratory Animal Service Center
of the Chinese University of Hong Kong. They were maintained in an
air-conditioned room with controlled temperature of 24 ± 2 °C and
humidity of 55 ± 15%, in a 12 h light/darkness cycle regulation and
were fed laboratory chow and water ad libitum. All animal experiments
were conducted in accordance with the University Laboratory Animals
Service Center's guidelines on animal experimentation with approval
from the Animal Ethnics Committee of the University. Tumorigenicity
was investigated by tumor xenograft experiments. The athymic female
nude mice of 6–8 weeks old were injected with 100 μl suspension of
CFTR overexpressing cells or vector control MDA-231 cells (about
5 × 106) subcutaneously. Mice injected with saline were used as sham
control. Tumor formation in nude mice was monitored about a 6 week
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with tumor size larger than 1 cm in any dimension were terminated.
The tumor size was calculated according to the following formula:
0.5234 × [long diameter (short diameter)2]. For metastatic model, six-
to eight week old female nude mice were transplanted with 1 × 106
MDA-231 cells through the lateral tail vein under sterile conditions. All
micewere sacriﬁced 35 days after injection by perfusion. Lungswere col-
lected, ﬁxed and sectioned (5 μm) for HE (hematoxylin–eosin) staining.
Number and size of tumor foci were countered and calculated.
2.6. Correlation with breast cancer prognosis
Breast cancer tissues and normal background tissues were collected
in the Department of Surgery, Cardiff University School of Medicine,
Cardiff, UK. These tissues were collected immediately after mastectomy
and snap frozen in liquid nitrogen, with approval of the local ethics
committee. Background normal mammary tissues were removed from
the same patients. The pathologist veriﬁed the normal background
and cancer specimens, and it was conﬁrmed that the background sam-
ples were free from tumor deposits. The median follow-up period was
120 months (June 2004). We subgroup the patients to Surv 1, 2, 3,
and 4. Surv 1 represents those patients alive andwell 10 years after sur-
gery, Surv 2 and 3 represent patients with metastasis and local recur-
rence, respectively within the follow-up period. Surv 4 represents
patients who died from breast cancer. Thus, Surv 2, 3, and 4 indicate
patients in disease, including those with metastasis, local recurrence,
and death compared to Surv 1, which is considered as disease free.
RNA extraction, reverse transcription–PCR and quantitative PCR were
performed as described before [25]. Statistical analysis was performed
using theMinitab (Minitab Ltd., Coventry, UK) statistical software pack-
age (version 14). The two sample t test was used for normally distributed
data. Kaplan–Meier survival analysis was performed using SPSS statistical
software (version 11; SPSS. Chicago, IL, USA). Differenceswere considered
to be statistically signiﬁcant at P b 0.05.
2.7. Statistical analyses
Data are presented as themean ± SEMand Student's unpaired t test
was used for 2 groups of statistical analysis. Differences between groups
were analyzed using Prism 4 (GraphPad, Inc., San Diego, CA). A p value
b0.05 was considered statistically signiﬁcant.
3. Results
3.1. TGF-β1-induced EMT in breast cancer cells involves downregulation
of CFTR
TGF-β is considered as a key mediator of EMT during physiological
processes which is frequently and abundantly expressed in various tu-
mors and induces EMT in cancer cells during cancer progression [26]. In
addition, TGFβ signaling has been linked to CF pathogenesis [27,28]. As
a ﬁrst step to investigate the role of CFTR in the EMT process, we treated
non-invasive breast cancer cell line MCF-7 with TGF-β1, which has been
shown to be a potent EMT inducer in MCF-7 cells, for 48 h. As shown in
Fig. 1a a′ & b′, 2 μg/ml TGF-β1 dramatically downregulated epithelial
marker, E-cadherin, in MCF-7 cells. Interestingly, along with the loss of
E-cadherin, the expression of CFTR was signiﬁcantly suppressed by TGF-
β1 suggesting that downregulation of CFTR is associated with EMT
(Fig. 1a & b). In order to investigatewhether suppression of CFTR function
per se could induce an EMT phenotype in MCF-7, the cells were treated
with speciﬁc CFTR inhibitors, inh172 or GlyH101, in the absence of TGF-
β1. Our immunoﬂuorescent staining result showed that treatment with
10 μMinh172mimicked the effect of TGF-β1, downregulating the expres-
sion of E-cadherin (Fig. 1c). The downregulation of epithelial marker and
upregulation of mesenchymal marker by CFTR inhibitors (inh172 and
GlyH101) were further veriﬁed by our western blot analysis (Fig. 1d &Appendix A: Supplementary Fig. 1). In addition, we demonstrated that
suppression of CFTR function by its inhibitors promoted both cell invasion
and migration of MCF-7 cells (Fig. 1e & f). Taken together, these results
indicate that suppression of CFTR function elicits an EMT phenotype
with enhanced metastatic capability in MCF-7 cells.
3.2. Knockdown/overexpression of CFTR induces/inhibits EMT and malignant
phenotypes of breast cancer cells
The observed involvement of CFTR in mediating the effect of TGF-β1
on EMT prompted us to ask whether CFTR gene manipulation could
alter EMT and malignant phenotypes in breast cancer cells. First, we
establishedMCF-7 cells with CFTR knockdown using a lentiviral expres-
sion system. As shown in Fig. 2a, CFTR knockdown signiﬁcantly
inhibited the expression of E-cadherin and Occludin, whereas it
upregulated the expression of Laminin γ2 at the protein levels in
MCF-7 (Fig. 2a). In addition, whereas CFTR knockdown did not have
any effects on cell proliferation (Appendix A: Supplementary Fig. 2),
suppression of CFTR dramatically increased the invasive and migratory
capacity of MCF-7 cells (Fig. 2b & c). Taken together, these data suggest
that either the inhibition of CFTR channel function or the knockdown is
sufﬁcient to trigger EMT.
As EMT has been considered as a reversible processing, we
overexpressed wild-type CFTR in MDA-231, which is known as a highly
invasive breast cancer cell line with typical mesenchymal features, to
explore the possible effect of CFTR on its reversion to epitheliumpheno-
type. As shown in Fig. 2d, CFTR expressionwas signiﬁcantly increased in
CFTR overexpressing stable cells compared to control vector transduced
cells. Consequently, we observed that the overexpression of CFTR
caused an increased level of epithelialmarker E-cadherin and a decreased
level of mesenchymal marker vimentin in theMDA-231 cells (Fig. 2d). In
addition, functional assay demonstrated that the overexpression of CFTR
repressed invasive and migratory ability in MDA-231 cells (Fig. 2e & f).
Taken together, these data strongly suggest an important role of CFTR in
regulating the EMT process and malignancy in breast cancer.
3.3. CFTR inhibits lung metastasis in vivo
We further tested whether we could suppress metastatic potential of
breast cancer in vivo by overexpressing CFTR in nude mice. First, to test
the tumorigenic capability, we established xenograft models by subcuta-
neous injection of MDA-231 cells transduced with CFTR or the corre-
sponding empty vector into the right ﬂanks of mice, and the primary
tumormass of tumor-bearingmiceweremonitoreduntil sacriﬁce. Our re-
sults exhibited no differences in primary tumor growth between control
vector transfected and CFTR overexpressing MDA-231 injected mice
(Fig. 3a–c). We then tested the possible effects of CFTR overexpression
on the metastatic potential of MDA-231 cancer cells. We injected MDA-
231 cells expressing either control vector or CFTR into the tail vein of
nude mice and examined signs of metastasis in the lungs 35 days after
injection. Detailed quantiﬁcation was conducted with H&E staining on
the lung sections. We found that while 100% (6/6) of the mice injected
with MDA-231-empty vector-transfected cells developed metastases at
the end of the experiments, only 50% (3/6) of the mice injected
with CFTR overexpressing MDA-231 cells presented lung metastases
(Fig. 3e). Moreover, the tumor burden in the control vector group and
the CFTR overexpression group had a signiﬁcant difference after 35 days
(Fig. 3f). These data, along with the results of in vitro analysis, indicate
the role of CFTR as a metastasis suppressing gene.
3.4. Anti-metastatic effect of CFTR is mediated by NFκB targeting uPA
The urokinase-type plasminogen activator (uPA) is a secreted serine
proteinase that converts plasminogen to plasmin. The binding of uPA to
its speciﬁc membrane receptor, uPAR, initiates a proteolytic cascade for
degrading ECMwhich in turn regulates cell migration and invasiveness.
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lation ofmetastatic phenotype of cancer including EMT [29,30]. In an at-
tempt to explore by which mechanism(s) CFTR suppresses EMT and
metastatic phenotype of breast cancer, we found that CFTR knockdown
signiﬁcantly increased uPA expression and secreted uPA activity in
MCF-7 cells (Fig. 4a & b), whereas overexpression of CFTRwas sufﬁcient
to decrease uPA activity in MDA-231 cells (Fig. 4c), indicating that uPA
activity is CFTR dependent in these cancer cells. Since uPA is known to
be activated by NFκB and defective CFTR has been shown to result in
endogenous activation of NFκB [24,31], we further tested whether the
effect of CFTR on uPA was mediated by NFκB. Indeed, in this study, we
found that CFTR knockdown leads to enhanced expression of NFκB
p65 and p50 in MCF-7 (Fig. 4d). In addition, we showed that the tran-
scriptional activity of both p65 and p50 was signiﬁcantly increased inCFTR knockdown MCF-7 cells compared to control cells (Fig. 4e). More
importantly, we demonstrated that NFκB inhibitor curcumin reversed
the upregulation of uPA in CFTR knockdown MCF-7 cells (Fig. 4f). If
the tumor-suppressing effects of CFTR are largely due to alteration in
NFκB activities, the effects observed with either CFTR knockdown or
overexpression should be reversed by altering the NFκB activity. To
test this, we used CFTR knockdown MCF-7 cells as our model system
to test whether CFTR repression-induced EMT may be reversed by
inhibiting NFκB activity. We treated both control and CFTR knockdown
MCF-7 cells with different concentrations of curcumin and evaluated
their changes in EMT markers and metastatic phenotypes. As shown
in Appendix A: Supplementary Fig. 3, curcumin signiﬁcantly reversed
themolecular changes of EMT in the CFTR knockdown cell.More impor-
tantly, the inhibition of NFκB activity completely abrogated the CFTR
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Fig. 4. Involvement ofNFκB and uPA inmediating the tumor-suppressing effects of CFTR. (a) RT-PCR analysis shows increased expression of uPA inCFTRknockdownMCF-7 cells compared
to vector control cells. Quantiﬁcation analysis of data is expressed as the Mean ± SEM from three independent experiments, *p b 0.05. (b) The activity of uPA is upregulated in CFTR
knockdownMCF-7 cells comparedwith vector control cells. Quantiﬁcation analysis of data is expressed as theMean ± SEM from three independent experiments, p b 0.05. (c) The activity
of uPA is downregulated in CFTR overexpressingMDA-231 cells, *p b 0.05. Data aremean ± SEM from three independent experiments. Quantiﬁcation analysis of data is expressed as the
Mean ± SEM from three independent experiments, *p b 0.05. (d) Representative western blot image shows increased expression of NFκB p65 (sc-109) and p50 (sc-7178) in
MCF-7CFTRsiRNA cells compared to control cells, whereas decreased in MDA-231 cells overexpressing CFTR. (e) Luciferase activity assay shows the transcriptional activity of p65 and p50 is
upregulated in CFTR knockdown MCF-7 cells. Quantiﬁcation analysis of data is expressed as the Mean ± SEM from three independent experiments, *p b 0.05, **p b 0.01. (f) Representative
PCR image showing the upregulation of uPA is abrogated by NFκB inhibitor curcumin in MCF7 CFTRshRNA cells as determined by RT-PCR. (g,h) MCF-7 miR-LacZ or miR-CFTR transduced
cells were incubated with either 10 μM or 25 μM NFκB inhibitor curcumin. (g) Invasion assay shows that 10 μM and 25 μM curcumin signiﬁcantly reverse the enhanced invasion in
MCF-7CFTRshRNA cells without inhibitor treatment. Quantiﬁcation analysis of data is expressed as the Mean ± SEM from three independent experiments, *p b 0.05. (h) Wound healing
migration assay shows that the treatment with 25 μM curcumin reverses the enhanced migration in MCF-7CFTRshRNA cells. Quantiﬁcation analysis of data is expressed as the Mean ±
SEM from three independent experiments, *p b 0.05.
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indicating that the upregulation of NFκB activity targeting uPA is the
major mechanism leading to the observed increased malignancies in-
duced by CFTR knockdown in these cancer cells. Interestingly, a fast-
growing body of evidence has indicated that CFTR might play a more
complex and extensive role thanwe previously thought [32,33]. Indeed,
besides uPA, we have found that downregulation of CFTR inMCF-7 cells
regulates a variety of genes involved in EMT and tumormetastasis using
PCR array (Fig. 5a & b).
3.4.1. CFTR downregulation is correlated with poor prognosis of breast
cancer
Having established the effect of CFTR on the regulation of EMT and
metastasis in breast cancer cell lines, we went on to investigate the
expression pattern of CFTR in clinical breast cancer samples. First, weanalyzed the immunoreactivity of CFTR in parafﬁn-embedded sections
of normal breast (n = 3) and breast cancer tissues (n = 17). Among
these breast cancer samples, 9 patients were diagnosed as invasive duc-
tal carcinoma (IDC), whereas 8 patients were diagnosed as invasive lob-
ular carcinoma (ILC). The immunohistochemical staining of CFTR was
scored in a semiquantitativemanner by examination of the cytoplasmic
and membrane staining intensity and compared with normal tissue.
Our results showed that in normal breast tissue (Fig. 6a), most luminal
epithelial cells showed a strong apical expression of CFTR (score 3).
However, the expression of CFTR was signiﬁcantly decreased and dis-
tributed diffusely in the cytoplasm of the breast cancer cells. 13 of 17
cases of breast cancer exhibited weak expression of CFTR (score ≤1,
Fig. 6a & b and Appendix A: Supplementary Table 2). We did not ﬁnd
any signiﬁcant difference in CFTR expression levels between IDC and
ILC. Moreover, we conﬁrmed CFTR downregulation in the Oncomine
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Fig. 5. CFTR knockdown induces alteration in a variety of EMT genes. (a) EMT-focused PCR array analysis shows the upregulated EMT-promoting genes between control and CFTR
knockdown MCF-7 cells. Data were analyzed by comparing 2−ΔCt of the normalized data. Fold changes were calculated relative to the control MCF-7. Quantiﬁcation analysis of data is
from two repeated experiments and an arbitrary cut-off of N2-fold change was used to identify genes that were differentially expressed between samples. (b) RT-PCR analysis conﬁrms
the expression proﬁles of some altered genes indicated in the PCR array.
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ses [34,35], signiﬁcant downregulation of CFTR was observed in cancer
samples compared with normal breast tissue (Fig. 6c). Next, we
attempted to evaluate the prognostic potential of CFTR in different co-
horts of breast cancer patients. The CFTR expression was ﬁrst examined
in accordance with patients' Nottingham Prognostic Index (NPI) using
Real-time qPCR. Statistical analysis showed that patients with poor
prognosis (NPI3) had signiﬁcantly lower levels of CFTR transcripts,
(p = 0.028) when compared to patients with good prognosis (NPI1)
(Fig. 6d). In another cohort of patients, regarding clinical outcomes
after a median 120 month's follow-up, the patients with poor prognosis,
including thosewithmetastasis, local recurrence, and death due to breast
cancer, had signiﬁcantly lower levels of CFTR transcripts compared toa Normal Breast cancer
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Fig. 6. CFTR downregulation is correlated with poor prognosis in breast cancer. (a) Immunohist
abnormally distributed CFTR in cancer sample compared to adjacent normal tissue. The red bo
analysis showing the expression of CFTR in breast cancer is signiﬁcantly decreased compared to
the immunostaining raw scores between the control and tumors, given the fact that the analytic
proﬁles of breast cancer samples show the signiﬁcant downregulation of CFTR in cancer samp
index in breast cancer. The NPI1 group (NPI score b 3.4; n = 58) represents patients with good
prognosis, while patients of the NPI3 group (NPI score N5.4; n = 15) had a poor prognosis, data
breast cancer patients. In a cohort of patients with 120 months follow-up, expression of CFTR
patients. Data are Mean ± SEM, *p b 0.05.disease-free patients, who have no cancer and live well 10 years after
surgery (p b 0.05, Appendix A: Supplementary Fig. 4). The patients who
died from breast cancer had the lowest expression levels of CFTR com-
pared to that of disease-free patients (p = 0.017) (Fig. 6e). Thus, reduced
expression of CFTR is signiﬁcantly associated with disease progression
and poor prognosis in breast cancer.
4. Discussion
Although there has been recent interest in the risk of various cancers
in CF patients, studies on the role of CFTR in the pathogenesis of cancer
are very limited. In the present study, we have revealed a previously
undeﬁned role of CFTR in breast cancer progression/metastasis. Our gainb
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aremean ± SEM, *p b 0.05. (e) Low CFTR expression is associatedwith poor prognosis in
is signiﬁcantly decreased in patients who died of breast cancer compared to disease-free
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downregulation of CFTR inMCF-7 promotes breast cancermalignant phe-
notype which is associated with altered cellular invasion, migration and
EMT,whereas overexpression of CFTR suppresses EMT and invasive prop-
erties in MDA-231 cells (Fig. 2). More importantly, while overexpression
of CFTR has no signiﬁcant effect on tumorigenicity in nudemice xenograft
model, excessive CFTR dramatically suppresses breast cancer lungmetas-
tasis in vivo (Fig. 3). Taken together, these results clearly demonstrate that
CFTR, while it has no signiﬁcant effect on tumorigenicity, is inversely
associated with the progression and metastasis of breast cancer. Intrigu-
ingly, the ﬁndings of this study are supported by clinical observation
that while there was no difference in breast cancer rate between ΔF508
carrier and non-carrier, breast cancers arising from ΔF508 CFTR carriers
were at least grade III based on combined pathological and cytological
grading system, indicating that defective CFTR is related to breast cancer
progression [36].
Localized at the apical membrane of epithelial cells, CFTR has been
reported to be required for the normal organization and function of
cell junctions, and loss of CFTR has been shown to lead to abnormally
low transepithelial resistance and loss of epithelial integrity [37]. On
the other hand, loss of one of the key components of adherens junctions,
E-cadherin, often occurs in the later stages of tumorigenesis and con-
tributes to EMT, which represents a crucial step in metastasis. In our
study, we have clearly demonstrated that suppression of CFTR function
leads to loss of E-cadherin whereas overexpression of CFTR results in
upregulation of E-cadherin, which is in line with observed changes of
EMT process and malignant phenotypes in breast cancer cell lines
(Figs. 1 & 2). In addition, we have found that TGFβ1, a potent EMT induc-
er, signiﬁcantly downregulates the expression of CFTR in MCF-7 cells
(Fig. 1a & b), suggesting that TGFβ1may induce thedisruption of cell po-
larity and EMT through downregulation of CFTR. Of note, it has been re-
ported that TGF-β receptors directly interact with core polarity protein,
Par6, at the level of adherens junctions, which is required for TGFβ-
dependent EMT in mammary gland epithelial cells, demonstrating the
importance of TGF-β-regulated cell polarity in EMT and the development
ofmetastasis [5]. Interestingly, apart fromTGF-β, other EMT-inducing fac-
tors, such as TNFα and HIF1α, have been demonstrated to downregulate
CFTR expression [38,39], indicating a central role of CFTRas a downstream
effector in mediating the effects of various EMT inducers.
By what mechanism does CFTR exert its effect on EMT? Increasing
evidence indicates that a defect of CFTR in the apical membrane of epi-
thelial cells results in endogenous activation of NFκB, which in turn re-
sults in excessive production of proinﬂammatory cytokines [22–24].
Thus, functional CFTR is required for controlling the NFκB-mediated in-
ﬂammatory signaling [31,40–42]. In the current study, we have shown
that the knockdown of CFTR results in NFκB activation in breast cancer
cell lines (Fig. 4d & e), consistent with the previous ﬁndings in other cell
types. More importantly, the CFTR knockdown-induced EMT and
invasive phenotype in MCF-7 cells are completely abrogated by a
NFκB inhibitor (Fig. 4g,h), curcumin, indicating that enhanced EMT
and malignant phenotype in CFTR knockdown cells may be attributed
to NFκB activation. Of note, a study in 2005 found that curcumin-
stimulated CFTR, suggesting its therapeutic use in the treatment of CF.
However, further studies are needed to further explore this proposed
mechanism of curcumin and its role in CF treatment [31,43]. The NFκB
family of transcription factors plays pivotal roles in both promoting
andmaintaining an invasive phenotype of cancer [44,45].Wirth and co-
workers have identiﬁed NFκB as a central mediator of EMT in a mouse
model of breast cancer progression [6]. Speciﬁcally, NFκB transcription-
ally regulates the master regulator genes that represses epithelial phe-
notype or activates mesenchymal phenotype, such as snail, twist1 and
vimentin. Of particular interest, NFκB can activate uPA, which has
been well established to play a central role in extracellular matrix deg-
radation, invasion, and metastasis during cancer development [46].
Moreover, overexpression of uPA and uPAR has been shown to be asso-
ciated with adverse prognosis in various malignancies [8], includingbreast cancer [47,48]. In our study, we have demonstrated that the ex-
pression and activity of uPA are inversely associated with CFTR expres-
sion in breast cancer cells (Fig. 4a–c). In addition, we have shown that
the NFκB inhibitor curcumin reverses the upregulation of uPA in CFTR
knockdown MCF-7 cells (Fig. 4f). These results indicate that the EMT-
suppressing effect of CFTR is associated with its ability to alter NFκB ac-
tivity targetinguPA. Of interest,whilewehave demonstrated previously
that CFTR suppressed prostate cancer progression through miR-193b-
medicated regulation of uPA [12], we did not detect any signiﬁcant
change of miR-193b in breast cancer cell lines with CFTR manipulation.
These ﬁndings indicate that CFTR may regulate metastatic process
through distinct tissue-speciﬁc pathways in different types of cancer.
On the other hand, the effect of CFTR on EMT may also be mediated by
different pathways in the same cancer type. Indeed, we have found
that downregulation of CFTR in MCF-7 cells increased the expression
of various ECM and cell invasion-related genes (Fig. 5). Among the dif-
ferentially expressed genes, the upregulation of ﬁbronectin, vimentin
and collagens has been closely associated with the EMT process. Sox10
and twist have been well established as key transcriptional factors in-
volved in mesenchymal transition in both development and pathologi-
cal conditions, such as cancer. In addition, Wnt, Bmp and EGF activated
pathways play critical roles in the modulation of EMT and cancer pro-
gression. These results indicate the possible involvement of other path-
ways directly or indirectly linked to NFκB activation in breast cancer
metastasis, the details of which require further investigation.
The present study has also demonstrated that CFTR expression is ab-
normally distributed in primary humanbreast cancer and inversely corre-
lated with the poor prognosis of the patients. While the expression of
CFTR is mostly localized in the apical membrane of normal luminal epi-
thelial cells, the staining of CFTR is found diffusely distributed in the cyto-
plasm of cancer cells (Fig. 6a), indicating that apical membrane
expression/function of CFTR is required for the maintenance of epithelial
polarity and suppression of EMT and cancer malignancy. It is noteworthy
that CFTR expression is not related to ER and PR status (Appendix A:
Supplementary Table 2 and Supplementary Fig. 5). While the mecha-
nisms regulating CFTR expression in cancer remain largely elusive, the
CFTR gene is reported to be frequently hypermethylated and/or mutated
in various primary cancer samples and cell lines, whichmay contribute to
cancer malignancy as demonstrated in the present study. The present
ﬁnding that CFTR is aberrantly expressed in breast cancer samples, and
its correlationwith poor breast cancer progression,warrants future inves-
tigations on CFTR methylation or mutation in breast cancer patients,
which are likely to provide attractive and novel targets for prognosis
and therapeutic intervention of breast cancer.
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